IF aged (16-month-old) male and female genetically heterogeneous UM-HET3 mice are administered a triple-combination regimen consisting of continuous dietary rapamycin (14 ppm microencapsulated) plus acarbose (1000 ppm; collectively "RaAc"), co-administered with intermittent oral gavage of Dasatinib + Quercetin (D+Q; 5 mg/kg dasatinib + 50 mg/kg quercetin, daily for 3 consecutive days every two weeks),

THEN median and 90th-percentile lifespan will be extended beyond the established RaAc-alone ceiling of +37% in males and +28% in females — measurable as a statistically significant further gain of ≥8% median lifespan in males versus RaAc controls — and the RaAc + D+Q arm will produce significantly greater lifespan extension than an isodose RaAc + Nav-Gal arm tested in parallel, with the lifespan advantage of D+Q over Nav-Gal being most pronounced in the rapamycin-co-treated context,

BECAUSE the following causally connected mechanistic steps operate in sequence:

1. RaAc saturates the metabolic and nutrient-sensing axes of mammalian aging: rapamycin inhibits mTORC1-driven cellular hyperfunction and suppresses the mTOR-dependent translational output of the SASP, while acarbose reduces postprandial glucose and insulin spikes, collectively producing the largest pharmacologically achieved lifespan extension in an ITP-certified outbred mammalian model — yet leaves accumulated senescent cell burden physically intact in aged tissues. (Rapamycin+acarbose +37% male lifespan)[Evidence Set: Strong et al. 2022 ITP data, synthetic_research_questions_feedback.md]

2. Aged UM-HET3 mice at 16 months carry a significant accumulated burden of p16^INK4a^- and p21-positive senescent cells across multiple tissues (adipose, liver, kidney, lung), which rapamycin suppresses but does not eliminate; these cells constitutively activate paracrine damage signaling even at reduced SASP levels, representing a residual damage load that cannot be resolved by mTOR inhibition alone. [SPECULATIVE that residual SASP at rapamycin-suppressed levels is still pathological over long timescales, though directionally supported by senostatic vs. senolytic literature]

3. D+Q clears this accumulated senescent cell burden through a mechanism entirely orthogonal to mTOR status: dasatinib inhibits pro-survival tyrosine kinases (including Src-family kinases and PDGFR) that senescent cells upregulate as anti-apoptotic defenses (Senescent Cell Anti-Apoptotic Pathways, SCAPs), while quercetin inhibits PI3K and disables the FOXO4–p53 interaction that senescent cells exploit to resist apoptosis. This SCAP-inhibition mechanism does not require lysosomal senescence-associated β-galactosidase (SA-β-gal) activity for activation, making it mechanistically orthogonal to rapamycin co-treatment. (D+Q intermittent oral gavage in 24-month mice extended remaining lifespan ~36%)[https://doi.org/10.1038/s41591-018-0092-9]

4. [SPECULATIVE — novel mechanistic link]: Nav-Gal (galactose-conjugated navitoclax) ...

SENS category: LysoSENS

Key references: • doi.org/10.1038/s41591-018-0092-9] • doi.org/10.1126/science.abe4832] • doi.org/10.1038/s41591-018-0092-9]. • doi.org/10.1038/s41591-018-0092-9